Novavax

Novavax, Inc.
TypePublic
Nasdaq: NVAX
ISINUS6700024010
IndustryBiotechnology
Founded1987 (1987)
Headquarters,
United States Edit this on Wikidata
Area served
Worldwide
Key peopleJohn C. Jacobs (CEO)
James P. Kelly (CFO)
ProductsVaccines
RevenueDecrease US$682 million (2024)
Increase -US$248 million (2024)
Increase -US$187 million (2024)
Total assetsDecrease US$1.560 billion (2024)
Total equityIncrease -US$623 million (2024)
Number of employees
952 (2025)
Websitewww.novavax.com Edit this at Wikidata
Footnotes
Stanley Erck (right) and Gregory Glenn (left) at the biotech labs in Gaithersburg during the visit of the Governor of Maryland
Novavax research and development laboratories in Gaithersburg

Novavax, Inc., based in Gaithersburg, Maryland, develops vaccines to counter infectious diseases. The company developed the Novavax COVID-19 vaccine, now commercialized by Sanofi. The company also develops vaccines for influenza, respiratory syncytial virus (RSV), avian flu, shingles, Clostridioides difficile, and malaria.

Novavax develops proprietary immune-stimulating saponin-based immunologic adjuvants at a wholly owned Swedish subsidiary, Novavax AB. One of these, Matrix-M, is used in the Novavax COVID-19 vaccine.